You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
Johnson and Johnson
Merck
AstraZeneca

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,962,629

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,962,629
Title:Tricyclic compounds
Abstract: The invention provides a compound of Formula (I) ##STR00001## pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Inventor(s): Wishart; Neil (Jefferson, MA), Argiriadi; Maria A. (Wayland, MA), Calderwood; David J. (Framingham, MA), Ericsson; Anna M. (Shrewsbury, MA), Fiamengo; Bryan A. (Worcester, MA), Frank; Kristine E. (Grayslake, IL), Friedman; Michael M. (Brookline, MA), George; Dawn M. (Charlton, MA), Goedken; Eric R. (Worcester, MA), Josephsohn; Nathan S. (Boston, MA), Li; Biqin C. (Southborough, MA), Stewart; Kent D. (Gurnee, IL), Wallace; Grier A. (Sterling, MA), Wang; Lu (Northborough, MA), Woller; Kevin R. (Antioch, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:12/481,028
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,962,629

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-001 Aug 16, 2019 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,962,629

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072086   Start Trial
Argentina 079234   Start Trial
Australia 2009257602   Start Trial
Australia 2010326108   Start Trial
Australia 2016201825   Start Trial
Australia 2018201663   Start Trial
Australia 2020201390   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Baxter
Colorcon
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.